3Mark Estesl NA, Homoud MK, Link MS, et al. Assessment of risk for sudden cardiac death[ J ]. Curr Probl Carbiol, 2002,27 (6):246- 266.
4Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin - resistant thromboxame biosynthesis and the risk of myocardiovascular death in patients at high risk for cardiovascular event [J]. Circulation,2002,105(14):1650-1655.
5Gum PA, Kottke - Marchant K, Welsh PA, et al. A prospective blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease[ J]. J Am Coll Cardiol,2003, 41(6):966-968.
6McCullough PA, Omland T, Maisel AS.B- type natriuretic peptides: a diagnostic breakthrough for clinicians [J]. Rev Cardiovasc Med,2003,107(13): 1764 - 1769.
7Vitovec B,Delgado R,Zewail A, et al.Prolonged QT interval and high B - type natriuretic peptide level together predict mortality in patients with advanced heart failure [J]. Circulation, 2003,107(13): 1776 - 1779.
8Albert CM, Ma J, Rifai N, et al. Prospective study of C - reactive protein, homocysteine and plasma lipid levels as predictor of sudden cardiac death [J]. Circulation, 2002,105(22) :2574 - 2576.
9Soeki T, Tamura Y, Shinohara M, et al. Plasma concentration of fibrinolytic factors in the subacute phase of myocardial infarction predict recurrent myocardial infarction of sudden cardiac death [ J ]. Int J Cardiol,2002,85(2 - 3) :277 - 283.
10Inliano S, Fisher SG, Karasik PE, et al. QSR duration and mortality in patients with congestive heart failure[J]. Am Heart J, 2002,143(6):401 - 416.
